Chinese medical device companies are expanding into Europe to offset declining domestic sales caused by an ongoing anti-corruption probe in hospitals.
Government-backed hospital purchases of medical devices in China fell about 12 per cent year on year in the first five months of 2026, partly due to a new anti-corruption probe into hospitals, according to a July 10 report by Linda Shu, head of China healthcare research at HSBC. This has weighed on revenue for major Chinese medical device makers in the first half of the year.
Jenscare Scientific, based in Ningbo in eastern Zhejiang province, is among firms seeking relief overseas. On July 8 the company filed with the Hong Kong Stock Exchange that its LuX-Valve Plus had received CE certification under the European Union’s Medical Device Regulation.
The device, the second of its kind worldwide to gain approval, allows replacement of a damaged tricuspid valve through a vein rather than open-chest surgery. Jenscare Scientific described the approval as a milestone in its international strategy.